Anti-MUC1 aptamer: A potential opportunity for cancer treatment

被引:115
|
作者
Nabavinia, Maryam Sadat [1 ]
Gholoobi, Aida [2 ]
Charbgoo, Fahimeh [1 ,3 ]
Nabavinia, Mahboobeh [4 ]
Ramezani, Mohammad [1 ,5 ]
Abnous, Khalil [3 ,6 ]
机构
[1] Mashhad Univ Med Sci, Sch Pharm, Dept Pharmaceut Biotechnol, Mashhad, Iran
[2] Mashhad Univ Med Sci, Sch Med, Dept Modern Sci & Technol, Mashhad, Iran
[3] Mashhad Univ Med Sci, Pharmaceut Res Ctr, Mashhad, Iran
[4] Univ Illinois, Dept Bioengn, Chicago, IL USA
[5] Mashhad Univ Med Sci, Nanotechnol Res Ctr, Mashhad, Iran
[6] Mashhad Univ Med Sci, Sch Pharm, Dept Med Chem, Mashhad, Iran
关键词
antibody; aptamer; mucin 1 or MUC1; targeted therapy; EPITHELIAL OVARIAN-CANCER; BREAST-CANCER; MONOCLONAL-ANTIBODY; TARGETED DELIVERY; CHITOSAN NANOPARTICLES; EMERGING CLASS; DNA APTAMERS; IN-VITRO; MUC1; THERAPY;
D O I
10.1002/med.21462
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Mucin 1 (MUC1) is a protein usually found on the apical surface of most normal secretory epithelial cells. However, in most adenocarcinomas, MUC1 is overexpressed, so that it not only appears over the entire cell surface, but is also shed as MUC1 fragments into the blood stream. These phenomena pinpoint MUC1 as a potential target for the diagnosis and treatment of cancer; consequently, interest has increased in MUC1 as a molecular target for overcoming cancer therapy challenges. MUC1 currently ranks second among 75 antigen candidates for cancer vaccines, and different antibodies or aptamers against MUC1 protein are proving useful for tracing cancer cells in the emerging field of targeted delivery. The unique properties of MUC1 aptamers as novel targeting agents, and the revolutionary role that MUC1 now plays in cancer therapy, are the focus of this review. Recent advancements in MUC1-targeted cancer therapy are also assessed.
引用
收藏
页码:1518 / 1539
页数:22
相关论文
共 50 条
  • [1] Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine
    Qi, WM
    Schultes, BC
    Liu, D
    Kuzma, M
    Decker, W
    Madiyalakan, R
    HYBRIDOMA AND HYBRIDOMICS, 2001, 20 (5-6): : 313 - 324
  • [2] Nanoparticle conjugated with aptamer anti-MUC1/Y for inflammatory arthritis
    Correa, Luana Barbosa
    Pinto, Suyene Rocha
    Rebelo Alencar, Luciana Magalhaes
    Missailidis, Sotiris
    Rosas, Elaine Cruz
    de Oliveira Henriques, Maria das Gracas Muller
    Santos-Oliveira, Ralph
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2022, 211
  • [3] Development, Characterization, and In Vivo Evaluation of a Novel Aptamer (Anti-MUC1/Y) for Breast Cancer Therapy
    Khan, Huma
    Makwana, Vaidehi
    Santos, Sofia Nascimento dos
    Bonacossa de Almeida, Carlos Eduardo
    Santos-Oliveira, Ralph
    Missailidis, Sotiris
    PHARMACEUTICS, 2021, 13 (08)
  • [4] Anti-MUC1 Aptamer as Carrier Tool of the Potential Radiosensitizer Phenanthroline in MCF-7 Breast Cancer 1,10 Cells
    Alves, Lais N.
    Missailidis, Sotiris
    Lage, Claudia A. S.
    De Almeida, Carlos Eduardo B.
    ANTICANCER RESEARCH, 2019, 39 (04) : 1859 - 1867
  • [5] Molecular Dynamics Simulation Analysis of Anti-MUC1 Aptamer and Mucin 1 Peptide Binding
    Rhinehardt, Kristen L.
    Srinivas, Goundla
    Mohan, Ram V.
    JOURNAL OF PHYSICAL CHEMISTRY B, 2015, 119 (22): : 6571 - 6583
  • [6] Talc and anti-MUC1 antibodies
    Muscat, J
    Huncharek, M
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (11) : 2679 - 2679
  • [7] Potential of Anti-MUC1 Antibodies as a Targeted Therapy for Gastrointestinal Cancers
    Bose, Mukulika
    Mukherjee, Pinku
    VACCINES, 2020, 8 (04) : 1 - 21
  • [8] Solution structure of a truncated anti-MUC1 DNA aptamer determined by mesoscale modeling and NMR
    Baouendi, Meriem
    Cognet, Jean A. H.
    Ferreira, Catia S. M.
    Missailidis, Sotiris
    Coutant, Jerome
    Piotto, Martial
    Hantz, Edith
    du Penhoat, Catherine Herve
    FEBS JOURNAL, 2012, 279 (03) : 479 - 490
  • [9] Bacteriophage Qβ as a promising carrier for anti-MUC1 cancer vaccine
    Yin, Zhaojun
    Finn, M. G.
    Huang, Xuefei
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [10] Talc and anti-MUC1 antibodies - Response
    Cramer, DW
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (11) : 2680 - 2680